Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.56 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 8/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2561968 | 0.95 | HRH3 (0.61) | HRH3ACACBPRMT5WDR77HRH1 | |
| Oxalic Acid SCHEMBL3548999 | 0.86 | HRH3 (0.42) | HRH3ACACBPRMT5WDR77NAMPT | |
| SCHEMBL2561454 | 0.81 | HRH3 (0.46) | HRH3ACACBPRMT5WDR77CYP2D6 | |
| SCHEMBL2560214 | 0.81 | HRH3 (0.45) | HRH3PRMT5WDR77HRH1 | |
| SCHEMBL2564105 | 0.80 | ACACB (0.52) | HRH3ACACBPRMT5WDR77 | |
| SCHEMBL2560796 | 0.79 | DRD2 (0.50) | HRH3ACACBPRMT5WDR77CYP2D6 | |
| Oxalic Acid SCHEMBL3553401 | 0.79 | HRH3 (0.64) | HRH3HRH1CYP2D6 | |
| SCHEMBL2566679 | 0.79 | ACACB (0.46) | HRH3ACACBPRMT5WDR77CYP2D6 | |
| SCHEMBL3550839 | 0.78 | ROCK1 (0.38) | HRH3PRMT5WDR77CYP2D6 | |
| SCHEMBL2567353 | 0.77 | HRH3 (0.67) | HRH3HRH1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678807-B2 | Isoquinoline and benzo[H] isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of the histamine H3 receptor | SANOFI-AVENTIS (FR) | 2010-03-16 | — | — | US | disclosed |
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269199-A1 | ISOQUINOLINE AND BENZO[H]ISOQUINOLINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH1, HRH2 | HRH3 1/4885ACACB 4456/4885PRMT5 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.